Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $26.48, but opened at $25.88. Ascentage Pharma Group International shares last traded at $25.99, with a volume of 10,595 shares traded.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an "overweight" rating for the company.
Read Our Latest Report on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
The business has a 50-day simple moving average of $22.58.
Institutional Investors Weigh In On Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent SEC filing.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
